Sutro Biopharma
STRO
124 hedge funds and large institutions have $766M invested in Sutro Biopharma in 2021 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 50 increasing their positions, 44 reducing their positions, and 26 closing their positions.
21% more call options, than puts
Call options by funds: $258K | Put options by funds: $213K
14% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 44
0.73% less ownership
Funds ownership: 9.67% → 8.94% (-0.73%)
10% less funds holding
Funds holding: 138 → 124 (-14)
24% less capital invested
Capital invested by funds: $1.01B → $766M (-$243M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
54% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$10.3M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$8.42M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$4.11M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$3.95M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$48.2M |
| 2 |
Morgan Stanley
New York
|
-$11.4M |
| 3 |
Verition Fund Management
Greenwich,
Connecticut
|
-$7.18M |
| 4 |
CLOS
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
|
-$6.61M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$6.39M |
STRO Hedge Fund Activity: Q2 2021 in Review
124 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q2 2021, worth a combined $766M — down 24% from $1.01B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of STRO and 12 opened new positions — a net loss of 14 holders — while 44 trimmed existing stakes and 50 added.
The largest buyer was BlackRock, adding an estimated $10.3M. The largest seller was RA Capital Management, exiting entirely with an estimated $48.2M sold.
- 124 institutional investors held Sutro Biopharma (STRO) as of Q2 2021, down from 138 in Q1 2021.
- Funds reported $766M of Sutro Biopharma stock for Q2 2021, down 24% quarter-over-quarter.
- 12 funds opened new Sutro Biopharma positions in Q2 2021 and 26 closed out, a net change of -14 holders.
- The largest Sutro Biopharma buyer in Q2 2021 was BlackRock, an estimated $10.3M added.
- The largest Sutro Biopharma seller in Q2 2021 was RA Capital Management, an estimated $48.2M sold.
Based on aggregated 13F filings for Q2 2021.